Have you been diagnosed with advanced cancer that cannot be removed by surgery or has spread to a different part of the body (metastasis)? Has your disease has been getting worse on standard of care cancer treatment? If so, you may be able to take part in a research study looking at whether the experimental study drug, AI-081, is safe and well tolerated, and whether it is effective in treating advanced or metastatic cancer.
This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.
Are you planning on having an IUD placed? If you are already planning to get an IUD, this study gives the chance to receive extra pain medication during insertion. Everyone will receive standard pain medication, and 2/3 of volunteers will receive extra. We are looking to see if giving ketorolac pills 1-hour vs 2-hours before an IUD decreases pain levels. We would need 3 hours of in-person clinic time from volunteers. Compensation provided.
If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .
Do you have depression and are currently experiencing depression symptoms? We are conducting a treatment trial to see whether non-invasive brain stimulation that matches your brain waves can improve depression symptoms. This is a randomized controlled trial where participants will be randomly assigned to receive active or placebo (fake) stimulation. Compensation is provided.
Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.
Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.
Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.
Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.
Have you been diagnosed with HER2-low locally unresectable advanced or metastatic breast cancer? If so, you may be eligible for a study to investigate the efficacy treatment with Dato-DXd or T-DXd.